Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
  • WIIM
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
11 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For February 10, 2022

By Benzinga Insights
Today, 7:27 AM
  Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million.

ACB

Read More
7 minute read
  • Small Cap

BIOX: Bioceres Crop Solutions reports 1st quarter of fiscal 2022 financial results and reviews operational accomplishments. Bioceres received regulatory approval in Brazil for HB4 wheat flour for human consumption.

By Zacks Small Cap Research
Today, 7:27 AM
By Steven Ralston, CFA NASDAQ:BIOX READ THE FULL BIOX RESEARCH REPORT

BIOX

Read More
7 minute read
  • Small Cap

BIOX: Bioceres Crop Solutions reports 1st quarter of fiscal 2022 financial results and reviews operational accomplishments. Bioceres received regulatory approval in Brazil for HB4 wheat flour for human consumption.

By Zacks Small Cap Research
Today, 7:27 AM
By Steven Ralston, CFA NASDAQ:BIOX READ THE FULL BIOX RESEARCH REPORT

BIOX

Read More
2 minute read
  • FDA
  • News

Bioceres Crop Solutions Announces Regulatory Approval Of Drought Tolerant HB4 Wheat By Brazil’s CTNBio

By Benzinga Newsdesk
Today, 7:27 AM
Bioceres Crop Solutions Corp. ("Bioceres") (NASDAQ:BIOX), a fully integrated global provider of crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality, has

BIOX

Read More
6 minute read
  • Biotech
  • Earnings
  • FDA
  • General
  • Guidance
  • News
  • Offerings
  • Penny Stocks
  • Small Cap

The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance

By Shanthi Rexaline
Today, 7:27 AM
Here's a roundup of top developments in the biotech space over the last 24 hours.

ACIU

Read More
1 minute read
  • Earnings
  • News

Bioceres Crop Solutions Q1 Sales $66.91M Miss $82.21M Estimate

By Bill Haddad
Today, 7:27 AM
Bioceres Crop Solutions (AMEX:BIOX) reported quarterly sales of $66.91 million which missed the analyst consensus estimate of $82.21 million by 18.62 percent. This is a 57.96 percent increase over sales of $42.35

BIOX

Read More
18 minute read
  • Earnings
  • Markets
  • News
  • Pre-Market Outlook

Earnings Scheduled For November 10, 2021

By Benzinga Insights
Today, 7:27 AM
  Companies Reporting Before The Bell • LumiraDx (NASDAQ:LMDX) is projected to report quarterly loss at $0.24 per share on revenue of $94.32 million.

AACG

Read More
13 minute read
  • Analyst Ratings
  • Downgrades
  • Initiation
  • Intraday Update
  • Upgrades

Benzinga’s Top Ratings Upgrades, Downgrades For October 8, 2021

By Benzinga Insights
Today, 7:27 AM
Upgrades

ALLE

Read More
1 minute read
  • Analyst Ratings
  • Initiation
  • News
  • Price Target

Roth Capital Initiates Coverage On Bioceres Crop Solutions with Buy Rating, Announces Price Target of $21

By Benzinga Newsdesk
Today, 7:27 AM
Roth Capital initiates coverage on Bioceres Crop Solutions (NASDAQ:BIOX) with a Buy rating and announces Price Target of $21.

BIOX

Read More
10 minute read
  • Small Cap

BIOX: Bioceres Crop Solutions reports financial results and reviews operational achievements for the 2021 fiscal year

By Zacks Small Cap Research
Today, 7:27 AM
By Steven Ralston, CFA NASDAQ:BIOX READ THE FULL BIOX RESEARCH REPORT

BIOX

Posts navigation

Previous 1 2 3 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service